Zosyn is owned by Wyeth Pharms.
Zosyn contains Piperacillin Sodium; Tazobactam Sodium.
Zosyn has a total of 3 drug patents out of which 0 drug patents have expired.
Zosyn was authorised for market use on 22 October, 1993.
Zosyn is available in injectable;injection dosage forms.
Zosyn can be used as method of treating bacterial infections.
The generics of Zosyn are possible to be released after 14 April, 2023.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8133883 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) | |
US6900184 | WYETH PHARMS | Compositions containing pipercillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) | |
US7915229 | WYETH PHARMS | Compositions containing piperacillin and tazobactam useful for injection |
Apr, 2023
(2 months from now) |
Drugs and Companies using PIPERACILLIN SODIUM; TAZOBACTAM SODIUM ingredient
Market Authorisation Date: 22 October, 1993
Treatment: Method of treating bacterial infections
Dosage: INJECTABLE;INJECTION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic